Successfull treatment of high risk hepatoblastoma final results of the SIOPEL 3 trial of the International Childhood Liver Tumours Strategy Group

被引：0
|
作者：
Zsiros, Jozsef
Maibach, R.
Brugieres, L.
Shafford, E.
Brock, P.
Czauderna, P.
Aronson, D.
MacKinlay, G.
Otte, J.
Plaschkes, J.
Childs, M.
Perilongo, G.
机构：
[1] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[2] Swiss Grp Clin Canc Res, Bern, Switzerland
[3] Inst Gustave Roussy, Paris, France
[4] UKCCSG, Ctr Data, Leicester, Leics, England
[5] Great Ormond St Hosp Sick Children, London WC1N 3JH, England
[6] Med Univ Gdansk, Gdansk, Poland
[7] Acad Med Ctr, Amsterdam, Netherlands
[8] Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland
[9] Univ Louvain, Brussels, Belgium
[10] Univ Childrens Hosp, Bern, Switzerland
[11] Univ Padua, Padua, Italy
来源：
PEDIATRIC BLOOD & CANCER | 2007年 / 49卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：420 / 420
页数：1
相关论文
共 50 条
  • [21] Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial
    Derdeyn, Colin P.
    Chimowitz, Marc I.
    Lynn, Michael J.
    Fiorella, David
    Turan, Tanya N.
    Janis, L. Scott
    Montgomery, Jean
    Nizam, Azhar
    Lane, Bethany F.
    Lutsep, Helmi L.
    Barnwell, Stanley L.
    Waters, Michael F.
    Hoh, Brian L.
    Hourihane, J. Maurice
    Levy, Elad I.
    Alexandrov, Andrei V.
    Harrigan, Mark R.
    Chiu, David
    Klucznik, Richard P.
    Clark, Joni M.
    McDougall, Cameron G.
    Johnson, Mark D.
    Pride, G. Lee, Jr.
    Lynch, John R.
    Zaidat, Osama O.
    Rumboldt, Zoran
    Cloft, Harry J.
    LANCET, 2014, 383 (9914): : 333 - 341
  • [22] PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group
    Fuchs, Michael
    Goergen, Helen
    Kobe, Carsten
    Eich, Hans
    Baues, Christian
    Greil, Richard
    Sasse, Stephanie
    Zijlstra, Josee M.
    Lohri, Andreas
    Rosenwald, Andreas
    von Tresckow, Bastian
    Diehl, Volker
    Kuhnert, Georg
    Dietlein, Markus
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2018, 132
  • [23] Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
    de Boer, Stephanie M.
    Powell, Melanie E.
    Mileshkin, Linda
    Katsaros, Dionyssios
    Bessette, Paul
    Haie-Meder, Christine
    Ottevanger, Petronella B.
    Ledermann, Jonathan A.
    Khaw, Pearly
    Colombo, Alessandro
    Fyles, Anthony
    Baron, Marie-Helene
    Jurgenliemk-Schulz, Ina M.
    Kitchener, Henry C.
    Nijman, Hans W.
    Wilson, Godfrey
    Brooks, Susan
    Carinelli, Silvestro
    Provencher, Diane
    Hanzen, Chantal
    Lutgens, Ludy C. H. W.
    Smit, Vincent T. H. B. M.
    Singh, Naveena
    Do, Viet
    D'Amico, Romerai
    Nout, Remi A.
    Feeney, Amanda
    Verhoeven-Adema, Karen W.
    Putter, Hein
    Creutzberg, Carien L.
    LANCET ONCOLOGY, 2018, 19 (03): : 295 - 309
  • [24] Treatment of patients up to 60 years with high risk AML: Final results of the AML SHG-Hannover 01/99 trial.
    Krauter, Juergen
    Heil, Gerhard
    Hoelzer, Dieter
    Ottmann, Oliver G.
    Martin, Hans
    Lubbert, Michael
    Finke, Jurgen
    Heit, Woltgang F. W.
    Fiedler, Walter
    Kanz, Lothar
    Schlimok, Gunter
    Kirchner, Hartmut H.
    Raghavachar, Aruna
    Brugger, Wolfram
    Ganser, Arnold
    BLOOD, 2006, 108 (11) : 132A - 132A
  • [25] TREATMENT REDUCTION IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE GERMAN HODGKIN STUDY GROUP
    Borchmann, P.
    Goergen, H.
    Kobe, C.
    Fuchs, M.
    Greil, R.
    Zijlstra, J. M.
    Huettmann, A.
    Markova, J.
    Meissner, J.
    Feuring-Buske, M.
    Bentz, M.
    Dierlamm, J.
    Kuehnhardt, D.
    Lohri, A.
    Novak, U.
    Eichenauer, D.
    Eich, H.
    Baues, C.
    Stein, H.
    Diehl, V.
    Kuhnert, G.
    Dietlein, M.
    Engert, A.
    HAEMATOLOGICA, 2017, 102 : 24 - +
  • [26] Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)
    Hishiki, Tomoro
    Matsumoto, Kimikazu
    Ohira, Miki
    Kamijo, Takehiko
    Shichino, Hiroyuki
    Kuroda, Tatsuo
    Yoneda, Akihiro
    Soejima, Toshinori
    Nakazawa, Atsuko
    Takimoto, Tetsuya
    Yokota, Isao
    Teramukai, Satoshi
    Takahashi, Hideto
    Fukushima, Takashi
    Kaneko, Takashi
    Hara, Junichi
    Kaneko, Michio
    Ikeda, Hitoshi
    Tajiri, Tatsuro
    Nakagawara, Akira
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (05) : 965 - 973
  • [27] Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)
    Tomoro Hishiki
    Kimikazu Matsumoto
    Miki Ohira
    Takehiko Kamijo
    Hiroyuki Shichino
    Tatsuo Kuroda
    Akihiro Yoneda
    Toshinori Soejima
    Atsuko Nakazawa
    Tetsuya Takimoto
    Isao Yokota
    Satoshi Teramukai
    Hideto Takahashi
    Takashi Fukushima
    Takashi Kaneko
    Junichi Hara
    Michio Kaneko
    Hitoshi Ikeda
    Tatsuro Tajiri
    Akira Nakagawara
    International Journal of Clinical Oncology, 2018, 23 : 965 - 973
  • [28] Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study
    Leppa, Sirpa
    Jorgensen, Judit M.
    Karjalainen-Lindsberg, Marja-Liisa
    Beiske, Klaus
    Pedersen, Mette
    Drott, Kristina
    Pasanen, Annika
    Karihtala, Kristiina
    Mannisto, Susanna
    Meriranta, Leo
    Wold, Bente
    Brodtkorb, Marianne
    Fagerli, Unn Merete
    Larsen, Thomas S.
    Munksgaard, Lars
    Sunela, Kaisa
    Fluge, Oystein
    Jyrkkio, Sirkku
    Brown, Peter de Nully
    Holte, Harald
    BLOOD, 2022, 140 : 1768 - 1769
  • [29] Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).
    Joensuu, H.
    Eriksson, M.
    Hatrmann, J.
    Hall, K. Sundby
    Schutte, J.
    Reichardt, A.
    Schlemmer, M.
    Wardelmann, E.
    Ramadori, G.
    Al-Batran, S.
    Nilsson, B. E.
    Monge, O.
    Kallio, R.
    Sarlomo-Rikala, M.
    Bono, P.
    Leinonen, M.
    Hohenberger, P.
    Alvegard, T.
    Reichardt, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO).
    Joensuu, H.
    Eriksson, M.
    Hatrmann, J.
    Hall, K. Sundby
    Schutte, J.
    Reichardt, A.
    Schlemmer, M.
    Wardelmann, E.
    Ramadori, G.
    Al-Batran, S.
    Nilsson, B. E.
    Monge, O.
    Kallio, R.
    Sarlomo-Rikala, M.
    Bono, P.
    Leinonen, M.
    Hohenberger, P.
    Alvegard, T.
    Reichardt, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
12345